Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer

Low‑pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple‑negative breast cancer

Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium

Targeting Translation and the Cell Cycle Inversely Affects CTC Metabolism but Not Metastasis

DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts

Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping

Analytical performance of the FDA-cleared Parsortix®PC1 system

Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer

Request a meeting with